Lacosamide (Antiseizure Medication): Dosing, Contraindications, and Monitoring
Lacosamide is a voltage-gated sodium channel modulator approved for partial-onset seizures in adults and children ≥2 years, with levetiracetam and lamotrigine preferred as first-line agents in most clinical scenarios, but lacosamide serves as an effective add-on therapy with favorable tolerability and minimal drug interactions. 1
Dosing Guidelines
Standard Adult Dosing
- Initial dose: Start at 50 mg twice daily (100 mg/day)
- Titration: Increase by 100 mg/day at weekly intervals
- Maintenance dose: 200-400 mg/day in two divided doses (maximum 400 mg/day in clinical trials)
- Loading dose (IV): Not typically recommended in the pivotal trials, though the medication can be administered IV with equivalent tolerability to oral formulation 2
Pediatric Dosing (Off-Label in Young Children)
- Children <4 years: 7-15.5 mg/kg/day divided in two doses, with efficacy demonstrated at these ranges 3
- Status epilepticus (pediatric): 10 mg/kg IV loading dose appears safe and effective, with total 24-hour doses averaging 13.8 mg/kg 4
- Neonates: Significantly higher doses (up to 22 mg/kg/day in 4 divided doses) may be required to achieve therapeutic levels, though this is highly individualized 5
Special Populations
Renal Impairment:
- Creatinine clearance 10-30 mL/min: Reduce dose by 25-50%
- Severe renal dysfunction or dialysis: Therapeutic drug monitoring (TDM) is strongly recommended as pharmacokinetics are significantly altered 6
Hepatic Impairment:
- Mild-to-moderate: No dose adjustment typically required
- Severe: Use with caution; data limited
Elderly:
- Consider TDM as pharmacokinetics may be altered 6
Therapeutic Drug Monitoring
Reference Ranges
The traditional reference range of 10-20 mg/L is problematic and associated with increased toxicity. A more appropriate upper limit is 12 mg/L based on trough levels, with toxicity significantly increasing above this threshold 7.
- Optimal range: 2.2-12 mg/L (trough levels)
- When to monitor:
Critical Care Considerations
In ICU settings, organ dysfunction, polypharmacy, and extracorporeal devices (ECMO, renal replacement therapy, plasmapheresis) substantially alter lacosamide pharmacokinetics, necessitating TDM and dose adjustments 8.
Adverse Effects Profile
Common Adverse Effects
- Dizziness (most common)
- Headache
- Somnolence
- Back pain
- Injection site reactions (IV formulation)
All adverse effects in controlled trials were mild-to-moderate with no serious adverse events reported 2.
Cardiac Monitoring
- PR interval prolongation: Small dose-related increases observed 9
- Bradycardia: Rare but documented 4
- Recommendation: Obtain baseline ECG and monitor in patients with cardiac conduction abnormalities or on medications affecting cardiac conduction
Driving and Cognitive Function
- Acute administration: May impair driving performance initially
- Chronic administration: Does not result in clinically meaningful driving impairment 10
- Arousal-related adverse events are lower with lacosamide compared to carbamazepine 10
Contraindications and Precautions
Absolute Contraindications
- Hypersensitivity to lacosamide or any component
Relative Contraindications/Cautions
- Second- or third-degree AV block (without pacemaker)
- Severe cardiac conduction problems
- Known cardiac sodium channelopathies
- Pregnancy: Use only if benefit outweighs risk (limited data)
Drug Interactions
Lacosamide has minimal drug interactions compared to older antiepileptic drugs, which is a significant advantage 6. However:
- Enzyme-inducing AEDs (phenytoin, carbamazepine, phenobarbital): Significantly reduce lacosamide levels, requiring dose adjustment and TDM 6
- No significant interactions with valproate, lamotrigine, or levetiracetam
Clinical Context and Positioning
When to Use Lacosamide
Brain Tumor-Associated Epilepsy: Levetiracetam and lamotrigine are preferred first-line agents. Lacosamide serves as an effective add-on for refractory cases 1. Avoid enzyme-inducing agents (phenytoin, carbamazepine, phenobarbital) due to interactions with chemotherapy and targeted agents 1.
Status Epilepticus: Lacosamide is included as a second-line option alongside levetiracetam, valproate, and fosphenytoin for established status epilepticus 11. In pediatric status epilepticus, IV lacosamide at 10 mg/kg demonstrates 78% efficacy with 44% achieving seizure freedom 4.
Refractory Focal Epilepsy: In children <4 years with refractory focal seizures, lacosamide shows 42% responder rate (≥50% seizure reduction) with 17% achieving seizure freedom after 3 months 3. However, loss of efficacy occurs in 50% of initial responders by 12 months 3.
Advantages Over Older Agents
- No enzyme induction: Unlike phenytoin and carbamazepine
- Linear pharmacokinetics: Predictable dose-response
- Minimal drug interactions: Critical in polypharmacy settings
- IV-to-oral equivalence: Seamless transition between formulations 2
- Lower cognitive impairment: Compared to traditional agents
Common Pitfalls
Using the 10-20 mg/L reference range: This increases toxicity risk. Target trough levels ≤12 mg/L 7
Ignoring enzyme-inducing AED interactions: These significantly reduce lacosamide levels; always use TDM when combining 6
Inadequate cardiac monitoring: Always obtain baseline ECG, especially in patients with cardiac history or on QT-prolonging medications
Assuming pediatric doses scale linearly: Neonates and young infants may require substantially higher mg/kg doses to achieve therapeutic levels 5
Overlooking renal function: Lacosamide is 90% renally excreted; dose reduction mandatory in severe renal impairment 6
Premature discontinuation in responders: 50% of pediatric responders lose efficacy by 12 months, but this doesn't mean the drug should be abandoned—consider dose optimization with TDM 3
Safety in Vulnerable Populations
Neonatal Safety: Unlike phenobarbital, lacosamide does not cause apoptotic cell death in developing brains, making it a safer option for neonatal seizures when used with appropriate monitoring 12. Levetiracetam shares this favorable safety profile 12.